Lung Cancer Clinical Trial

Clinical Trial Finder Lung Cancer Trials

Comparing 3 Schedules of Alimta Plus Gemzar

See Locations Near You

Summary

The purpose of the study is to measure tumor response rates for three schedules of Alimta(LY231514) in combination with gemcitabine in patients with locally advanced or metastatic non small cell lung cancer who have received no prior chemotherapy regimen.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of non-small lung cancer
No prior chemotherapy
Able to care for self

Exclusion Criteria:

An ongoing infection
Pregnancy or breast feeding
Other serious medical condition
Cancer that has spread to the brain
Inability to take folic acid

Study is for people with:

Lung Cancer

Phase:

Phase 2

Study ID:

NCT00034606

Recruitment Status:

Completed

Sponsor:

Eli Lilly and Company

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You


Rochester Minnesota, , United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 2

Study ID:

NCT00034606

Recruitment Status:

Completed

Sponsor:


Eli Lilly and Company

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
Clinical Trials Can be Life-Saving for Some
When Should I Consider Clinical Trials?
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider